Protein A Prosorba

Protein S Deficiency

Urinary protein

Protein Z Deficiency

Protein requirements

Baxter eyes prophylactic use of FEIBA NF in hemophilia

Baxter International is seeking the US FDA's blessing to market FEIBA NF (anti-inhibitor coagulant complex), nanofiltered and vapor-heated, as a prophylaxis treatment in patients with hemophilia A o...

Baxter to seek US prophylactic use of extracted clotting factors

Baxter intends to file a biologics license application (BLA) with the US FDA this quarter to expand the US label of its hemophilia treatment FEIBA NF to include prophylactic use. FEIBA NF contains a...

Baxter seeks FDA approval for FEIBA NF drug

Baxter has submitted a biologics license application (BLA) supplement to the US Food and Drug Administration (FDA) for the approval of its prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant C...

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis...

Feiba NF: Phase III data

Feiba NF regulatory update

Baxter Submits Application for FDA Approval of FEIBA NF for Prophylactic Use in Hemophilia A ...

Baxter submits hemophilia drug for FDA approval

Baxter International filed a biologics license application with the FDA for approval to use FEIBA NF Nanofiltered and Vapor H -More- 

Factor VIII Bypassing Activity (FEIBA) assays: standardization and development of the 1st NIBSC Working Standard for FEIBA - results from a collaborative study.

Factor-Eight-Inhibitor-Bypassing-Activity (FEIBA) is a bypassing-agent used to control spontaneous bleeding or cover surgical interventions in Haemophiliacs who develop neutralizing antibodies against...

Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey.

Summary.  Long used in established industrialized nations to treat patients with haemophilia and inhibitors, factor eight inhibitor bypassing activity (FEIBA) has, in recent years, been introduced i...

Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery.

A growing number of publications have described the efficacy and safety of FEIBA as a first-line haemostatic agent for surgical procedures in haemophilia A patients with high-responding FVIII inhibito...

Experience of four UK comprehensive care centres using FEIBA for surgeries in patients with inhibitors.

Summary. Increasing evidence indicates that factor VIII (FVIII) inhibitor bypassing agents (FEIBA((R)) and NovoSeven((R))) can provide effective peri-operative haemostasis in haemophilia patients with...

Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.

Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other anticoagulants in clinical trials. Therefore, agents to reverse the anticoagulant e...